• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did FTSE Russell’s Reclassification and Dividend Streak Just Shift Bristol-Myers Squibb’s (BMY) Investment Narrative?

    Simply Wall St·07/11/2026 00:46:36
    語音播報
    • In late June 2026, index provider FTSE Russell removed Bristol-Myers Squibb from several Russell growth benchmarks and added it to the Russell 1000 Value-Defensive and Russell 1000 Defensive indices, while the board reaffirmed a US$0.63 quarterly dividend, extending a 17-year streak of annual dividend increases.
    • This reclassification underscores how Bristol-Myers Squibb is increasingly viewed as a defensive, income-oriented pharmaceutical company, with index membership now reinforcing its dividend-focused, lower-volatility profile for institutional investors.
    • Next, we’ll examine how Bristol-Myers Squibb’s shift into value and defensive indices reshapes its investment narrative and perceived risk-return profile.

    Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

    Bristol-Myers Squibb Investment Narrative Recap

    To own Bristol-Myers Squibb today, you need to believe its diversified pipeline and partnerships can offset looming patent cliffs while its dividend remains a key part of the return story. The June 2026 shift into Russell value and defensive indices does not directly change the near term earnings catalyst, but it may affect who owns the stock and how they view risk, especially around patent expiries and pricing pressure.

    The most relevant recent announcement here is the reaffirmed US$0.63 quarterly dividend, extending a 17-year streak of annual increases. In the context of Bristol-Myers Squibb’s move into value and defensive indices, this steady payout reinforces the stock’s role as an income vehicle even as investors weigh upcoming earnings reports and the ability of newer drugs to offset future revenue losses.

    Yet behind this more defensive profile, investors should be aware of the timing and severity of upcoming patent expiries...

    Read the full narrative on Bristol-Myers Squibb (it's free!)

    Bristol-Myers Squibb's narrative projects $40.1 billion revenue and $8.6 billion earnings by 2029. This implies a 6.2% yearly revenue decline but a $1.3 billion earnings increase from $7.3 billion today.

    Uncover how Bristol-Myers Squibb's forecasts yield a $62.96 fair value, a 9% upside to its current price.

    Exploring Other Perspectives

    BMY 1-Year Stock Price Chart
    BMY 1-Year Stock Price Chart

    Compared with the consensus view, the most bullish analysts were factoring in revenue of about US$43.5 billion and earnings of roughly US$10.4 billion by 2029, which is a far more optimistic narrative that could look quite different once the index reclassification and patent risk you have just read about are fully reflected in their models.

    Explore 8 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth over 2x more than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Seeking Other Investments?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.